TSXV - Delayed Quote CAD

Evome Medical Technologies Inc. (EVMT.V)

0.0100

+0.0050

+(100.00%)

At close: 1:43:52 PM EDT

Michael Dalsin Resigns as Chairman of the Board of Directors of Evome Medical Technologies

NEW YORK, April 09, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (“Evome”, the “Company”) (TSXV: EVMT) ‎announced the resignation of Michael Dalsin as Chairman of the Board of Directors. Mr. Chris Heath will remain on the Board and continues to work to capture shareholder value in the various assets held by Evome. “As a large shareholder, I joined the board to get a clear understanding of the state of affairs, survey the totality of the circumstances, and see what could be done to ma

GlobeNewswire 18 days ago

LNDZF
Evome Medical Technologies Provides Market Update

NEW YORK, March 28, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) is providing an update to shareholders today. As important background: Evome generates revenue from three main revenue lines: “DaMar”. This a business-to-business revenue line. Located in California, DaMar Plastics Manufacturing, Inc. (“DaMar”) offers contract manufacturing to a highly concentrated group of customers that then sell those products under their own brand name.“Biodex

GlobeNewswire 30 days ago

LNDZF
Evome Medical Technologies Appoints Michael Dalsin as Chairman of the Board of Directors; Increases Size of Board to Six

NEW YORK, March 17, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) ‎announces the appointment of Michael Dalsin as Chairman of the Board of Directors. Kenneth Kashkin, MD will take the role of Vice-Chairman. Bill Garbarini will retain his role as COO while stepping off the Board of Directors. Chris Heath was also appointed as a new Director increasing the size of the Board of Directors from five to six. Mr. Dalsin is best known in Canada as the former Chair

GlobeNewswire last month

LNDZF
CLARIFICATION: Evome Medical Technologies Announces Significant Debt Restructuring

SHIRLEY, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) issued a press release on Monday, February 10, 2025 announcing the details of an amendment (the “Amendment”) to the forbearance agreement dated August 4, 2023 between ‎the Company, Biodex Rehab Systems, LLC (“Biodex Rehab”), a wholly owned subsidiary of the Company, and ‎Biodex Medical Systems, Inc. (“Biodex Medical”), a wholly owned subsidiary of Biodex Rehab, and Mirion ‎Technologies (

GlobeNewswire 2 months ago

LNDZF
Evome Medical Technologies Announces Significant Debt Reduction and Restructuring

SHIRLEY, N.Y., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) has announced a significant reduction in its overall ‎debt, strengthening its financial position, as a result of the execution of an amendment (the “Amendment”) to the forbearance agreement dated August 4, 2023 between the Company, Biodex Rehab Systems, LLC (“Biodex Rehab”), a wholly owned subsidiary of the Company, and Biodex Medical Systems, Inc. (“Biodex Medical”), a wholly owned subs

GlobeNewswire 2 months ago

LNDZF
Evome Medical Technologies Grants Restricted Stock Units to New Chief Operating Officer

SHIRLEY, N.Y., Jan. 20, 2025 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) is pleased to announce that the Company’s Board of Directors has approved the grant of 1,000,000 restricted stock units (RSUs) to William Garbarini in connection with his appointment as Chief Operating Officer, effective November 22, 2024. The RSUs were granted under the Company’s Amended and Restated 2023 Equity Incentive Plan, will vest over a period of 24 months, and upon vesting will

GlobeNewswire 3 months ago

LNDZF
Evome Medical Technologies Posts Third Quarter 2024 Results, Generates $424,000 in Adjusted EBITDA on Stable Revenues, Further Reduces Debt

Launches Evome Medical Products Distribution Company, Appoints Bill Garbarini Chief Operating Officer Adding Plan for a broader portfolio of Life Science ProductsSHIRLEY, N.Y., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Shirley, New York, November 25, 2024 – Evome Medical Technologies Inc. (the “Company”) (TSXV: EVMT) today reported financial results for the third quarter ended September 30, 2024‎. Among other financial highlights, the Company generated $424,000 in positive Adjusted EBITDA1 for the quart

GlobeNewswire 4 months ago

LNDZF
Evome Medical Technologies Announces Results From Its Annual General and Special Meeting of Shareholders

SHIRLEY, N.Y., Nov. 08, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today announced ‎the results from its annual general and special meeting of shareholders held on November 8, 2024 (the ‎‎“Meeting”) in Shirley, New York. The total number of shares represented in person or by proxy at the Meeting was ‎‎‎18,991,213‎, representing 31.2% of the total issued and outstanding voting shares of the Company.‎ All matters placed before shareholders were

GlobeNewswire 5 months ago

LNDZF
Evome Medical Technologies Reviews Highlights of Low-CapEx Revenue Growth Plan

Posts updated corporate presentation to website Reminder: Conference call to be held on August 19th to discuss Q2 2024 financial results SHIRLEY, N.Y., Aug. 15, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) highlights its low-CapEx plan for growing revenue in an updated corporate presentation now available at www.evomemedical.com/investor. The presentation, to be used during investor meetings planned for next month in New York, Vancouver, Montre

GlobeNewswire 8 months ago

LNDZF
Evome Medical Technologies Reports Second Quarter 2024 Financial Results

Stabilizes business with a return to positive Adjusted EBITDAPromotes Gordon Bean to Chief Financial OfficerAnnounces August 19th conference call to discuss financial results SHIRLEY, N.Y., Aug. 12, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. ‎(the “Company” or “Evome”) (TSXV: EVMT) today reported financial results for the second quarter ended June 30, 2024, featuring $421,000 in positive Adjusted EBITDA1, a reduction in debt, financial performance momentum and significant progress

GlobeNewswire 8 months ago

LNDZF
Evome Medical Technologies Retains irlabs for Investor Relations Services

NEW YORK, July 03, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) is pleased to announce it has entered into an agreement ("Agreement") with IR Labs Inc. ("irlabs") to provide the Company with investor relations and communications services. “We look forward to this partnership with irlabs as we work to raise our profile in the investment community,” said Mike Seckler, CEO. “In tandem with their expert team, we’re confident we can amplify our stor

GlobeNewswire 9 months ago

LNDZF
Evome Medical Technologies Announces Securities Issuances

NEW YORK, June 14, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) announces it has received conditional approval from the TSX Venture Exchange (the “TSXV”) to complete a shares for services transaction with Beacon Securities Limited (“Beacon”) pursuant to ‎which the Company will issue Beacon ‎504,286 ‎common ‎shares of the Company at a deemed price of ‎$0.1983 per share in satisfaction of $100,000 of advisory services. The shares issuable will be

GlobeNewswire 10 months ago

LNDZF
Evome Medical Technologies Announces Update Call with CEO Mike Seckler for Tuesday, June 4, 2024; Provides Update on Strong Q2

NEW YORK, June 03, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today provided details on preliminary estimated revenues and margins from April and May 2024, the first two months of the second quarter. Mike Seckler, Chief Executive Officer of the Company, will also hold a call to update shareholders on the first quarter financials, second quarter progress and future plans of the Company. Revenue Growth Update for Q2 2024 For April and May 2024,

GlobeNewswire 10 months ago

LNDZF
Evome Medical Technologies Announces Biodex Generated 100% Sales Growth Comparing April 2024 to January 2024, Plans to Shed Remaining Non-Core Units to Pay Off Remaining Acquisition Debt

Posting Q1 Financials, Provides Updates on Strong Q2NEW YORK, May 30, 2024 (GLOBE NEWSWIRE) -- Evome Medical Technologies Inc. (the “Company” or “Evome”) (TSXV: EVMT) today reported continued progress on its turn-around plan. Evome has grown revenue at its core business unit, Biodex Medical Systems, Inc. (“Biodex”), while reducing total debt significantly for the third straight quarter. The Company announced it generated 100% revenue growth in its Biodex business unit in April 2024 compared to J

GlobeNewswire 10 months ago

LNDZF

Performance Overview

Return	EVMT.V	S&P/TSX Composite index (^GSPTSE)
YTD	-91.67%	+0.72%
1-Year	-94.87%	+12.88%
3-Year	-98.82%	+17.41%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Evome Medical Technologies Inc. (EVMT.V)

Michael Dalsin Resigns as Chairman of the Board of Directors of Evome Medical Technologies

Evome Medical Technologies Provides Market Update

Evome Medical Technologies Appoints Michael Dalsin as Chairman of the Board of Directors; Increases Size of Board to Six

CLARIFICATION: Evome Medical Technologies Announces Significant Debt Restructuring

Evome Medical Technologies Announces Significant Debt Reduction and Restructuring

Evome Medical Technologies Grants Restricted Stock Units to New Chief Operating Officer

Evome Medical Technologies Posts Third Quarter 2024 Results, Generates $424,000 in Adjusted EBITDA on Stable Revenues, Further Reduces Debt

Evome Medical Technologies Announces Results From Its Annual General and Special Meeting of Shareholders

Evome Medical Technologies Reviews Highlights of Low-CapEx Revenue Growth Plan

Evome Medical Technologies Reports Second Quarter 2024 Financial Results

Evome Medical Technologies Retains irlabs for Investor Relations Services

Evome Medical Technologies Announces Securities Issuances

Evome Medical Technologies Announces Update Call with CEO Mike Seckler for Tuesday, June 4, 2024; Provides Update on Strong Q2

Evome Medical Technologies Announces Biodex Generated 100% Sales Growth Comparing April 2024 to January 2024, Plans to Shed Remaining Non-Core Units to Pay Off Remaining Acquisition Debt

Performance Overview